JP2024544565A - 養子細胞移入免疫療法を増強する方法 - Google Patents

養子細胞移入免疫療法を増強する方法 Download PDF

Info

Publication number
JP2024544565A
JP2024544565A JP2024528591A JP2024528591A JP2024544565A JP 2024544565 A JP2024544565 A JP 2024544565A JP 2024528591 A JP2024528591 A JP 2024528591A JP 2024528591 A JP2024528591 A JP 2024528591A JP 2024544565 A JP2024544565 A JP 2024544565A
Authority
JP
Japan
Prior art keywords
igg
cells
protein
car
cell transfer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024528591A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024544565A5 (enExample
Inventor
ランガナタン、ラグヴェール
ボッカーマン、ロバート
ロバートソン、アンナ－カリン
シェルマン、クリスティアン
ドッティ、ジャンピエトロ
Original Assignee
ハンサ バイオファーマ エービー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ハンサ バイオファーマ エービー filed Critical ハンサ バイオファーマ エービー
Publication of JP2024544565A publication Critical patent/JP2024544565A/ja
Publication of JP2024544565A5 publication Critical patent/JP2024544565A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4873—Cysteine endopeptidases (3.4.22), e.g. stem bromelain, papain, ficin, cathepsin H
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01096—Mannosyl-glycoprotein endo-beta-N-acetylglucosaminidase (3.2.1.96)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01169—Protein O-GlcNAcase (3.2.1.169)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/22—Cysteine endopeptidases (3.4.22)
    • C12Y304/2201—Streptopain (3.4.22.10)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2024528591A 2021-11-15 2022-11-14 養子細胞移入免疫療法を増強する方法 Pending JP2024544565A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163279398P 2021-11-15 2021-11-15
US63/279,398 2021-11-15
PCT/EP2022/081841 WO2023084095A2 (en) 2021-11-15 2022-11-14 Methods for enhancing adoptive cell transfer immunotherapies

Publications (2)

Publication Number Publication Date
JP2024544565A true JP2024544565A (ja) 2024-12-03
JP2024544565A5 JP2024544565A5 (enExample) 2025-11-25

Family

ID=84463039

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024528591A Pending JP2024544565A (ja) 2021-11-15 2022-11-14 養子細胞移入免疫療法を増強する方法

Country Status (7)

Country Link
US (1) US20250325640A1 (enExample)
EP (1) EP4433587A2 (enExample)
JP (1) JP2024544565A (enExample)
CN (1) CN119013396A (enExample)
AU (1) AU2022385450A1 (enExample)
CA (1) CA3237815A1 (enExample)
WO (1) WO2023084095A2 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4739775A1 (en) * 2023-07-07 2026-05-13 Emory University Recombinant glycosidases, pharmaceutical compositions, and uses in managing autoimmune or inflammatory conditions
CN122438692A (zh) * 2023-08-01 2026-07-21 英斯梅德股份有限公司 新型IgG蛋白酶及其使用方法
CN120334552B (zh) * 2025-06-12 2025-09-12 成都蓉生药业有限责任公司 一种人免疫球蛋白对非人种属细胞的adcp活性的检测试剂的组合、检测试剂盒及其检测方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015164739A1 (en) * 2014-04-25 2015-10-29 Bluebird Bio, Inc. Kappa/lambda chimeric antigen receptors
JP2017522384A (ja) * 2014-07-25 2017-08-10 ハンサ メディカル エービー 方法
JP2018510622A (ja) * 2015-02-12 2018-04-19 ハンサ メディカル アクチエボラグ システインプロテアーゼ
WO2021021989A1 (en) * 2019-08-01 2021-02-04 Memorial Sloan-Kettering Cancer Center Cells for improved immunotherapy and uses thereof
JP2023526480A (ja) * 2020-05-19 2023-06-21 ハンサ バイオファーマ エービー 養子細胞移入免疫療法を増強する方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201502306D0 (en) 2015-02-12 2015-04-01 Hansa Medical Ab Protein

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015164739A1 (en) * 2014-04-25 2015-10-29 Bluebird Bio, Inc. Kappa/lambda chimeric antigen receptors
JP2017522384A (ja) * 2014-07-25 2017-08-10 ハンサ メディカル エービー 方法
JP2018510622A (ja) * 2015-02-12 2018-04-19 ハンサ メディカル アクチエボラグ システインプロテアーゼ
WO2021021989A1 (en) * 2019-08-01 2021-02-04 Memorial Sloan-Kettering Cancer Center Cells for improved immunotherapy and uses thereof
JP2023526480A (ja) * 2020-05-19 2023-06-21 ハンサ バイオファーマ エービー 養子細胞移入免疫療法を増強する方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CLIN CANCER RES, vol. vol. 27(21), JPN6026031292, 15 April 2021 (2021-04-15), pages 5951 - 5960, ISSN: 0005918307 *
MOL THER, vol. vol. 29(12), JPN6026031291, 1 July 2021 (2021-07-01), pages 3398 - 3409, ISSN: 0005918306 *

Also Published As

Publication number Publication date
US20250325640A1 (en) 2025-10-23
EP4433587A2 (en) 2024-09-25
CA3237815A1 (en) 2023-05-19
CN119013396A (zh) 2024-11-22
WO2023084095A2 (en) 2023-05-19
WO2023084095A3 (en) 2023-07-20
AU2022385450A1 (en) 2024-06-13

Similar Documents

Publication Publication Date Title
ES2940607T3 (es) Receptores quiméricos modificados y composiciones y métodos relacionados
EP3378487B1 (en) Combination therapy using t cell redirection antigen binding molecule against cell having immunosuppressing function
JP7819119B2 (ja) 養子細胞移入免疫療法を増強する方法
US20250325640A1 (en) Methods for enhancing adoptive cell transfer immunotherapies
JP2023103318A (ja) 方法
Mason et al. Development of a fully canine anti-canine CTLA4 monoclonal antibody for comparative translational research in dogs with spontaneous tumors
ES2928167T3 (es) Composiciones y métodos para reducir las respuestas inmunitarias contra receptores de antígenos quiméricos
EP4051701A1 (en) Protease switch for dual targets chimeric antigen receptor t cell therapy
CN112469479A (zh) 治疗癌症和自身免疫性疾病的试剂和方法
JP2017519494A (ja) Ｏｘ４０ｌ融合タンパク質およびその使用
KR20160106170A (ko) 항체 및 항체-부하된 수지상 세포 매개된 요법을 위한 방법 및 조성물
RU2725807C2 (ru) Растворимый универсальный усиливающий adcc синтетический слитный ген, пептидная технология и их применение
Feng et al. PD-1 antibody interactions with Fc gamma receptors enable PD-1 agonism to inhibit T cell activation–therapeutic implications for autoimmunity
KR20230008144A (ko) Cd19를 표적화하는 키메라 항원 수용체 및 그의 용도
JP2022544580A (ja) 骨髄性悪性腫瘍を処置するためのキメラ抗原受容体
Mobergslien et al. Cancer cell-binding peptide fused Fc domain activates immune effector cells and blocks tumor growth
US20250084155A1 (en) Anti-hsp70 antibodies and therapeutic uses thereof
CA3174202A1 (en) Combination therapy involving anti-cd39 antibodies and adoptive cell therapy
US20240190965A1 (en) Targeting anti-human pd 1h/vista to treat hematologic disorders
US20240350630A1 (en) Compositions and methods of treating disease with chimeric antigen receptors to b cell maturation antigen (bcma)
Puri The Evaluation of MS4A4A and MS4A8B Expression in Hematopoietic Cells
Solomon Targeting regulatory T cells for therapeutic gain in cancer therapy
TW202413412A (zh) 在組合療法中能夠結合到ｃｄ２７之結合劑
Hammond Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein Michael D. Oberst, Catherine Augé, Chad Morris, Stacy Kentner, Kathy Mulgrew, Kelly McGlinchey, James Hair, Shino Hanabuchi, Qun Du 2, Melissa Damschroder 2, Hui Feng 2, 10, Steven Eck 3, Nicholas Buss 4, Lolke de Haan 4, Andrew J. Pierce 5, Haesun Park 6, Andrew
HK1261193A1 (en) Compositions and methods for reducing immune responses against chimeric antigen receptors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20240712

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240731

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20240712

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251114

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251114

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260727

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260728